ArticleFrontiers in pharmacology2026
LYVE-1 identifies asthma and drives PDGF-BB-induced proliferation, migration, and oxidative stress in airway smooth muscle cells via the PI3K/Akt pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthma is a chronic inflammatory airway disease characterized by airflow limitations, airway remodeling, and immune dysregulation. Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) has recently been implicated in inflammatory and remodeling processes in the body. However, its clinical significance and mechanistic role in asthma are unclear. This study aimed to investigate the association between soluble LYVE-1 (sLYVE-1) levels and asthma severity, airway inflammation, and remodeling, and to elucidate its regulatory role in airway smooth muscle cell (ASMC) activation via the PI3K/Akt signaling pathway. Methods: A total of 238 participants were enrolled, including 80 healthy controls, 72 patients with asthma who were in remission, and 86 patients with acute asthma. Clinical characteristics, pulmonary function parameters, inflammatory and remodeling biomarkers, and serum sLYVE-1 levels were assessed. Correlation analyses were performed to evaluate the relationship between sLYVE-1 and disease-related parameters. Mechanistic studies were conducted Results: Serum sLYVE-1 levels were significantly elevated in patients with asthma and progressively increased with disease severity. sLYVE-1 levels were inversely correlated with forced expiratory volume in one second (FEV1) and FEV1/FVC and positively correlated with total immune globulin E (IgE), eosinophil counts, T-helper cell type 2 (Th2) and T-helper cell type 17 (Th17) cell proportions, fractional exhaled nitric oxide (FeNO), type 2 cytokines, and airway remodeling-associated mediators, including vascular endothelial growth factor A (VEGF-A), stromal-derived factor 1α (SDF-1α), transforming growth factor-β1 (TGF-β1), matrix metalloproteinases-9 (MMP-9), and hyaluronan (all Conclusion: Elevated circulating sLYVE-1 levels are closely associated with asthma severity, airway inflammation, and airway remodeling. Mechanistically, LYVE-1 promoted PDGF-BB-induced ASMC activation through PI3K/Akt signaling, highlighting LYVE-1 as a potential biomarker and potential therapeutic target for asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.